MedTrace Logo

FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

NCT01439542 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-08-09

No results posted yet for this study

Summary

The purpose of this study is to examine the safety of a shorter course of radiation treatments combined with one year of androgen deprivation therapy. The study will test this treatment in men with high risk prostate cancer who have significant other illnesses or circumstances such that conventional long term radiotherapy and hormone therapy is not recommended by their physician or desired by the patient.

Conditions

Interventions

RADIATION

Stereotactic Body Radiation

Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week

DRUG

Luteinizing Hormone Releasing Hormone (LHRH) Agonist

12 months (2x6 month depot) of androgen suppression with LHRH agonist

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Glenn Bauman, MD · London Regional Cancer Program of the Lawson Health Research Institute

  • George Rodrigues, MD · London Regional Cancer Program of the Lawson Health Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01439542 on ClinicalTrials.gov